Plasma Translocator Protein Levels and Outcomes of Acute Ischemic Stroke: A Pilot Study

Wen Hung Chen, Hsu Ling Yeh, Chiung Wen Tsao, Li Ming Lien, Arthur Chiwaya, Javad Alizargar, Chyi Huey Bai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Translocator protein 18 kDa (TSPO) has been used as a biomarker of brain injury and inflammation in various neurological diseases. In this study, we measured the level of TSPO in acute ischemic stroke patients and determined its association with the degree of stroke severity and its ability to predict stroke functional outcomes. In total, 38 patients with moderate to severe acute ischemic stroke were enrolled. Demographic information, cerebral risk factors, and stroke severity were examined at the baseline. The National Institutes of Health Stroke Scale, modified Rankin Scale, and Barthal Index were assessed at discharge as measures of poor functional outcomes and severe disability. The baseline fasting plasma TSPO level was assessed within 24 h after the incident stroke and during hospitalization (on days 8-10). The proportion of patients with poor functional outcomes was significantly higher in the higher-TSPO group (compared to the lower group) in terms of clinical worsening (odds ratio (OR) = 11.69, 95% confidence interval (CI) = 2.08-65.6), poor functional outcomes (OR = 10.5, 95% CI = 1.14-96.57), and severe disability (OR = 4.8, 95% CI = 1.20-19.13). Plasma TSPO may be intimately linked with disease progression and worse functional outcomes in acute ischemic stroke patients.
Original languageEnglish
Pages (from-to)9831079
JournalDisease Markers
Volume2018
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Blood Proteins
Stroke
Plasmas
Proteins
Odds Ratio
Confidence Intervals
Biomarkers
Brain
Aptitude
Health
Association reactions
National Institutes of Health (U.S.)
Encephalitis
Brain Injuries
Disease Progression
Fasting
Hospitalization
Demography

Cite this

Plasma Translocator Protein Levels and Outcomes of Acute Ischemic Stroke: A Pilot Study. / Chen, Wen Hung; Yeh, Hsu Ling; Tsao, Chiung Wen; Lien, Li Ming; Chiwaya, Arthur; Alizargar, Javad; Bai, Chyi Huey.

In: Disease Markers, Vol. 2018, 01.01.2018, p. 9831079.

Research output: Contribution to journalArticle

Chen, Wen Hung ; Yeh, Hsu Ling ; Tsao, Chiung Wen ; Lien, Li Ming ; Chiwaya, Arthur ; Alizargar, Javad ; Bai, Chyi Huey. / Plasma Translocator Protein Levels and Outcomes of Acute Ischemic Stroke: A Pilot Study. In: Disease Markers. 2018 ; Vol. 2018. pp. 9831079.
@article{eb84961a167d4a74b67dd5a19c311b4f,
title = "Plasma Translocator Protein Levels and Outcomes of Acute Ischemic Stroke: A Pilot Study",
abstract = "Translocator protein 18 kDa (TSPO) has been used as a biomarker of brain injury and inflammation in various neurological diseases. In this study, we measured the level of TSPO in acute ischemic stroke patients and determined its association with the degree of stroke severity and its ability to predict stroke functional outcomes. In total, 38 patients with moderate to severe acute ischemic stroke were enrolled. Demographic information, cerebral risk factors, and stroke severity were examined at the baseline. The National Institutes of Health Stroke Scale, modified Rankin Scale, and Barthal Index were assessed at discharge as measures of poor functional outcomes and severe disability. The baseline fasting plasma TSPO level was assessed within 24 h after the incident stroke and during hospitalization (on days 8-10). The proportion of patients with poor functional outcomes was significantly higher in the higher-TSPO group (compared to the lower group) in terms of clinical worsening (odds ratio (OR) = 11.69, 95{\%} confidence interval (CI) = 2.08-65.6), poor functional outcomes (OR = 10.5, 95{\%} CI = 1.14-96.57), and severe disability (OR = 4.8, 95{\%} CI = 1.20-19.13). Plasma TSPO may be intimately linked with disease progression and worse functional outcomes in acute ischemic stroke patients.",
author = "Chen, {Wen Hung} and Yeh, {Hsu Ling} and Tsao, {Chiung Wen} and Lien, {Li Ming} and Arthur Chiwaya and Javad Alizargar and Bai, {Chyi Huey}",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/9831079",
language = "English",
volume = "2018",
pages = "9831079",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

TY - JOUR

T1 - Plasma Translocator Protein Levels and Outcomes of Acute Ischemic Stroke: A Pilot Study

AU - Chen, Wen Hung

AU - Yeh, Hsu Ling

AU - Tsao, Chiung Wen

AU - Lien, Li Ming

AU - Chiwaya, Arthur

AU - Alizargar, Javad

AU - Bai, Chyi Huey

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Translocator protein 18 kDa (TSPO) has been used as a biomarker of brain injury and inflammation in various neurological diseases. In this study, we measured the level of TSPO in acute ischemic stroke patients and determined its association with the degree of stroke severity and its ability to predict stroke functional outcomes. In total, 38 patients with moderate to severe acute ischemic stroke were enrolled. Demographic information, cerebral risk factors, and stroke severity were examined at the baseline. The National Institutes of Health Stroke Scale, modified Rankin Scale, and Barthal Index were assessed at discharge as measures of poor functional outcomes and severe disability. The baseline fasting plasma TSPO level was assessed within 24 h after the incident stroke and during hospitalization (on days 8-10). The proportion of patients with poor functional outcomes was significantly higher in the higher-TSPO group (compared to the lower group) in terms of clinical worsening (odds ratio (OR) = 11.69, 95% confidence interval (CI) = 2.08-65.6), poor functional outcomes (OR = 10.5, 95% CI = 1.14-96.57), and severe disability (OR = 4.8, 95% CI = 1.20-19.13). Plasma TSPO may be intimately linked with disease progression and worse functional outcomes in acute ischemic stroke patients.

AB - Translocator protein 18 kDa (TSPO) has been used as a biomarker of brain injury and inflammation in various neurological diseases. In this study, we measured the level of TSPO in acute ischemic stroke patients and determined its association with the degree of stroke severity and its ability to predict stroke functional outcomes. In total, 38 patients with moderate to severe acute ischemic stroke were enrolled. Demographic information, cerebral risk factors, and stroke severity were examined at the baseline. The National Institutes of Health Stroke Scale, modified Rankin Scale, and Barthal Index were assessed at discharge as measures of poor functional outcomes and severe disability. The baseline fasting plasma TSPO level was assessed within 24 h after the incident stroke and during hospitalization (on days 8-10). The proportion of patients with poor functional outcomes was significantly higher in the higher-TSPO group (compared to the lower group) in terms of clinical worsening (odds ratio (OR) = 11.69, 95% confidence interval (CI) = 2.08-65.6), poor functional outcomes (OR = 10.5, 95% CI = 1.14-96.57), and severe disability (OR = 4.8, 95% CI = 1.20-19.13). Plasma TSPO may be intimately linked with disease progression and worse functional outcomes in acute ischemic stroke patients.

UR - http://www.scopus.com/inward/record.url?scp=85055625497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055625497&partnerID=8YFLogxK

U2 - 10.1155/2018/9831079

DO - 10.1155/2018/9831079

M3 - Article

C2 - 30034558

AN - SCOPUS:85055625497

VL - 2018

SP - 9831079

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

ER -